Stockscreener 앱 받기
0.5901
14.58%
0.0751
시간 외 거래:
.60
0.0099
+1.68%
전일 마감가:
$0.515
열려 있는:
$0.535
하루 거래량:
5.57M
Relative Volume:
2.79
시가총액:
$130.07M
수익:
$8.95M
순이익/손실:
$-21.49M
주가수익비율:
-4.9175
EPS:
-0.12
순현금흐름:
$-29.24M
1주 성능:
+18.73%
1개월 성능:
+7.92%
6개월 성능:
-35.75%
1년 성능:
-51.23%
1일 변동 폭
$0.50
$0.5901
1주일 범위
$0.481
$0.5901
52주 변동 폭
$0.481
$1.61
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.5901 | 130.07M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital - Yahoo Finance
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts - Benzinga
D. Boral Capital Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
State Street Corp Acquires 45,483 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Here’s Why Lineage Cell Therapeutics Inc (AMEX: LCTX) Is An Attractive Investment Right Now - Stocks Register
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Down 1%Here's What Happened - MarketBeat
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround - Yahoo Finance
BioTime, Inc. : BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 - Marketscreener.com
LCTX stock touches 52-week low at $0.5 amid market challenges - Investing.com
Cell Therapy Manufacturing Market Growth in Future Scope - openPR
Lineage Cell Therapeutics FY2024 EPS Lifted by HC Wainwright - MarketBeat
HC Wainwright Issues Positive Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World
Stem cell therapy companies take different roads to reproducibility - BioCentury
Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com
Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio? - Yahoo Finance
Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner’s Portfolio? - Insider Monkey
Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock - Investing.com
Lineage Cell Therapeutics CFO Jill Howe buys $8,850 in stock By Investing.com - Investing.com Australia
Lineage Cell Therapeutics director buys $22,639 in common shares - Investing.com India
Lineage Cell Therapeutics director buys $22,639 in common shares By Investing.com - Investing.com Australia
Brian M. Culley Buys 40,000 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Stock - MarketBeat
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering - Business Wire
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Lineage Cell Therapeutics FY2024 EPS Boosted by Cantor Fitzgerald - MarketBeat
Lineage Cell Therapeutics secures $30 million in direct offering By Investing.com - Investing.com Australia
Lineage Cell Therapeutics tumbles after pricing $66M securities offering - MSN
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering - BioSpace
Lineage Cell Therapeutics secures $30 million in direct offering - Investing.com
Lineage Cell Therapeutics Launches $66M Direct Offering with Warrants for OpRegen Development | LCTX Stock News - StockTitan
Allogeneic Stem Cells Market Is Expected To Reach $2.0 Billion - openPR
D. Boral Capital Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy Recommendation - MSN
Boral Capital sets Buy rating for Lineage Cell stock - Investing.com
Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highl - GuruFocus.com
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Lineage Cell: Q3 Earnings Snapshot - Houston Chronicle
Lineage Cell Therapeutics Reports Q3 2024 Highlights - TipRanks
Earnings call: Lineage Cell Therapeutics reports solid Q3 progress By Investing.com - Investing.com Australia
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings: EPS of -$0.02, Revenue Surges to $3.8M, Beating Estimates - GuruFocus.com
Lineage Cell Therapeutics reports Q3 EPS (2c), consensus (3c) - TipRanks
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Lineage Cell Therapeutics's Earnings Outlook - Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - BioSpace
Lineage Cell Therapeutics to Report Q3 2024 Earnings on November 14 | LCTX Stock News - StockTitan
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
2.24%
자본화:
|
볼륨(24시간):